UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.